ZNTL Stock Analysis: Buy, Sell, or Hold?
ZNTL - Zentalis Pharmaceuticals, Inc. Common Stock
$3.97
0.29 (7.88%)
▲
5d:
+12.78%
30d:
-2.22%
90d:
+60.73%
BUY
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When ZNTL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ZNTL shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ZNTL shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ZNTL is currently trading at $3.97, which is considered extended relative to its 30-day fair value range of $3.59 to $3.97.
Technical Outlook: Technically, ZNTL is in a uptrend. Immediate support is located at $3.42, while resistance sits at $4.12. The stock is showing strong short-term momentum, up 7.9% recently.
Market Sentiment: ZNTL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.50 (+63.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ZNTL is in a uptrend. Immediate support is located at $3.42, while resistance sits at $4.12. The stock is showing strong short-term momentum, up 7.9% recently.
Market Sentiment: ZNTL has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.50 (+63.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.59 -
$3.97
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.9%)
- BULLISH: Trading 63.7% below Wall St target ($6.50)
Trading Range Analysis
30-Day Trading Range
$3.59 -
$3.97
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.42
Resistance Level
$4.12
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.55
Wall Street Target
$6.50
(+63.7%)
Share & Embed Analysis
Last updated: June 24, 2026 6:07 PM ET
Data refreshes hourly during market hours. Next update: 7:07 PM
Data refreshes hourly during market hours. Next update: 7:07 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZNTL showing a specific setup today?
Insider Activity (6 Months)
1
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Vincent Vultaggio
SELL
6894 shares
2026-02-10
Ingmar Bruns
SELL
335 shares
2026-02-09
Vincent Vultaggio
SELL
3379 shares
2026-02-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 59 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 61 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 60 BUY |
